TimesSquare Capital Management LLC Acquires 187,963 Shares of Guardian Pharmacy Services, Inc. $GRDN

TimesSquare Capital Management LLC grew its holdings in Guardian Pharmacy Services, Inc. (NYSE:GRDN) by 21.9% during the 4th quarter, HoldingsChannel reports. The firm owned 1,048,136 shares of the company’s stock after purchasing an additional 187,963 shares during the quarter. TimesSquare Capital Management LLC’s holdings in Guardian Pharmacy Services were worth $31,538,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Ameritas Investment Partners Inc. increased its stake in shares of Guardian Pharmacy Services by 26.5% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,647 shares of the company’s stock valued at $43,000 after purchasing an additional 345 shares during the last quarter. State of Alaska Department of Revenue bought a new position in shares of Guardian Pharmacy Services in the 3rd quarter valued at $30,000. Parkside Financial Bank & Trust increased its stake in shares of Guardian Pharmacy Services by 70.5% in the 3rd quarter. Parkside Financial Bank & Trust now owns 3,248 shares of the company’s stock valued at $85,000 after purchasing an additional 1,343 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Guardian Pharmacy Services by 31.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 7,899 shares of the company’s stock valued at $207,000 after purchasing an additional 1,872 shares during the last quarter. Finally, Marshall Wace LLP grew its position in Guardian Pharmacy Services by 13.9% during the 2nd quarter. Marshall Wace LLP now owns 15,442 shares of the company’s stock worth $329,000 after acquiring an additional 1,883 shares during the last quarter.

Insider Transactions at Guardian Pharmacy Services

In other Guardian Pharmacy Services news, insider Kendall Forbes sold 346,672 shares of the company’s stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $29.68, for a total value of $10,289,224.96. Following the sale, the insider owned 453,256 shares in the company, valued at approximately $13,452,638.08. The trade was a 43.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider David K. Morris sold 187,855 shares of the company’s stock in a transaction dated Friday, March 20th. The shares were sold at an average price of $29.68, for a total value of $5,575,536.40. Following the completion of the sale, the insider owned 254,472 shares in the company, valued at $7,552,728.96. This trade represents a 42.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 9,726,405 shares of company stock worth $288,679,700. 32.96% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

GRDN has been the subject of a number of recent research reports. Bank of America initiated coverage on Guardian Pharmacy Services in a report on Monday, April 27th. They issued a “buy” rating and a $42.00 target price for the company. Raymond James Financial reaffirmed an “outperform” rating and issued a $40.00 target price on shares of Guardian Pharmacy Services in a report on Thursday, March 12th. Truist Financial upped their target price on Guardian Pharmacy Services from $38.00 to $43.00 and gave the stock a “buy” rating in a report on Monday, April 13th. UBS Group reaffirmed a “buy” rating on shares of Guardian Pharmacy Services in a report on Thursday, March 12th. Finally, Jefferies Financial Group initiated coverage on Guardian Pharmacy Services in a report on Monday, March 30th. They issued a “buy” rating and a $44.00 target price for the company. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $41.33.

Guardian Pharmacy Services Stock Down 2.0%

Shares of GRDN opened at $35.89 on Tuesday. The business has a 50-day simple moving average of $36.37 and a two-hundred day simple moving average of $32.67. Guardian Pharmacy Services, Inc. has a 12-month low of $19.17 and a 12-month high of $41.36. The stock has a market cap of $1.79 billion, a PE ratio of 43.23, a PEG ratio of 2.43 and a beta of 0.09.

Guardian Pharmacy Services (NYSE:GRDN) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.29 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.05. Guardian Pharmacy Services had a return on equity of 30.72% and a net margin of 3.64%.The firm had revenue of $336.60 million for the quarter, compared to analyst estimates of $329.89 million. During the same quarter in the previous year, the company posted $0.22 EPS. The business’s revenue was up 2.2% on a year-over-year basis. On average, equities research analysts expect that Guardian Pharmacy Services, Inc. will post 1.17 EPS for the current year.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.